Implications of COVID-19 for the busy gastroenterologist

• Type: Another Publication in an International Scientific Journal
• Date: 2021

Authors

Ferreira Silva, J (Author) Other; Peixoto, A (Author) Other; Rodrigues Pinto, E (Author) FMUP; Macedo G (Author) FMUP

Journal

Title: European Journal of Gastroenterology & Hepatology

Vol. 33

Pages: 319-324

ISSN: 0954-691X

Publisher: Lippincott Williams & Wilkins

Indexing

ISI Web of Knowledge - 5 Citations

Other information

Authenticus ID: P-00T-QXJ

DOI: 10.1097/meg.0000000000001811

Abstract (EN): Coronavirus disease 2019 (COVID-19) is an infection caused by a novel coronavirus (SARS-CoV-2) originated in China in December 2020 and declared pandemic by WHO. This coronavirus mainly spreads through the respiratory tract and enters cells through angiotensin-converting enzyme 2 (ACE2). The clinical symptoms of COVID-19 patients include fever, cough, and fatigue. Gastrointestinal symptoms (diarrhea, anorexia, and vomiting) may be present in 50% of patients and may be associated with worst prognosis. Other risk factors are older age, male gender, and underlying chronic diseases. Mitigation measures are essential to reduce the number of people infected. Hospitals are a place of increased SARS-CoV-2 exposure. This has implications in the organization of healthcare services and specifically endoscopy departments. Patients and healthcare workers safety must be optimized in this new reality. Comprehension of COVID-19 gastrointestinal manifestations and implications of SARS-CoV-2 in the management of patients with gastrointestinal diseases, under or not immunosuppressant therapies, is essential. In this review, we summarized the latest research progress and major societies recommendations regarding the implications of COVID-19 in gastroenterology, namely the adaptations that gastroenterology/ endoscopy departments and professionals must do in order to optimize the provided assistance, as well as the implications that this infection will have, in particularly vulnerable patients such as those with chronic liver disease and inflammatory bowel disease under or not immunosuppressant therapies.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6